Treatment of inflammatory immunologic disease 2. Anti-cytokine therapies in inflammatory bowel disease.
Matsumoto
Takayuki
T
Department of Gastroenterology, Hyogo College of Medicine, Nishinomiya, Japan. matsut@hyo-med.ac.jp <matsut@hyo-med.ac.jp>
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068582:Certolizumab Pegol; D003424:Crohn Disease / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D004750:Enteral Nutrition; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D000069285:Infliximab; D011092:Polyethylene Glycols / Q000627:therapeutic use; D012074:Remission Induction; D012907:Smoking / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D014409:Tumor Necrosis Factor-alpha; D011092:Polyethylene Glycols; D000069285:Infliximab; D000068582:Certolizumab Pegol